We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Blood Test for Symptomatic Patients Aims to Revolutionize Cancer Diagnosis

By LabMedica International staff writers
Posted on 05 Jun 2023
Print article
Image: Galleri Multi-Cancer Test (Photo courtesy of GRAIL)
Image: Galleri Multi-Cancer Test (Photo courtesy of GRAIL)

Cancer patients generally seek medical attention from a primary care physician only after they begin experiencing related symptoms, such as unexplained weight loss, anemia, or abdominal discomfort. But these symptoms are complex as they can be attributed to various causes. Early detection and intervention of cancer can significantly enhance patient outcomes. Hence, there is a need for innovative tools to speed up cancer diagnosis and potentially eliminate the need for invasive and costly investigations, thus more effectively triaging patients with non-specific cancer symptoms. Now, a novel blood test, capable of detecting over 50 types of cancer, has shown promising results, accurately detecting cancer in two-thirds of more than 5,000 individuals who had consulted their physician due to suspected symptoms. Furthermore, in 85% of these cases, the test accurately identified the original location of the cancer.

The SYMPLIFY study, sponsored by The University of Oxford (Oxford, UK), is the first large-scale evaluation of a multi-cancer early detection (MCED) test from GRAIL, LLC (Menlo Park, CA, USA) among individuals who had consulted their GP due to suspected cancer symptoms. The study enrolled 6,238 participants, aged 18 and above, across England and Wales who were referred for urgent imaging, endoscopy, or other diagnostic methods due to symptoms suggestive of potential gynecological, lung, lower GI or upper GI cancer, or who had presented with non-specific symptoms. All participants provided a blood sample for DNA extraction and testing.

The MCED test from GRAIL detected a cancer signal in 323 individuals, with 244 of these receiving a cancer diagnosis, resulting in a positive predictive value (PPV) of 75.5%, negative predictive value (NPV) of 97.6%, and specificity of 98.4%. The overall sensitivity of the MCED test stood at 66.3%, ranging from 24.2% for stage I cancers to 95.3% for stage IV, and increasing with age and later cancer stage. The overall accuracy of the top CSO prediction following a positive MCED test was 85.2%. The study participants had a mean age of 62.1 years. Encouraged by the study outcomes, GRAIL now aims to broaden its market to include patients demonstrating symptoms linked to cancer, such as unexplained weight loss or abdominal pain.

GRAIL is planning to devise a new test specifically tailored for symptomatic patients, employing the same core technology used in its MCED test. The company hopes to have the new test available in months rather than years. Through a simple blood test, GRAIL aims to minimize reliance on costly scans or invasive biopsies as initial diagnostic procedures for cancer. Medical professionals have expressed enthusiasm about the potential impact of such blood tests in average-risk populations. These tests could serve as a crucial aid in making decisions concerning further diagnostic evaluation for patients. Nevertheless, the efficacy of such blood tests for early cancer detection and their influence on overall patient survival continues to be a topic of debate among clinicians.

“GRAIL’s earlier PATHFINDER study previously demonstrated that adding GRAIL’s MCED testing to standard of care screening more than doubled the number of cancers detected compared with standard screening alone in adults with no symptoms or suspicion of cancer. Now, the SYMPLIFY data confirm the potential benefit of methylation-based MCED blood tests as a diagnostic aid for use in the symptomatic patient population,” said Sir Harpal Kumar, President of GRAIL Europe. “These exciting results will inform our development of an optimized classifier for use in symptomatic patients with a suspicion of cancer.”

Related Links:
GRAIL, LLC

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.